HRT FINANCIAL LP purchased $97K of BJDX

HRT FINANCIAL LP purchased 64,047 shares of Bluejay Diagnostics, Inc. (BJDX) at $1.51 on 2026-07-09.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Jul 13, 2026, 7:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 13, 2026, 7:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BJDX
Bullish
medium confidence
Mentioned
$BJDX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BJDXBullishLow
01

Why it matters

A large owner reported an open-market buy, which can slightly improve sentiment but does not, by itself, change valuation drivers without accompanying operational updates.

02

Market read

Traders may monitor for follow-on ownership activity, but the filing alone is unlikely to drive a major repricing.

03

What to watch

No 10b5-1 plan is cited, but the filing also does not disclose intent, timeframe, or whether additional buys/sells are planned, limiting signal strength.

Relevance 4/10Novelty 4/10Timing: new Form 4 filed 2026-07-13, covering a 2026-07-09 purchase

Background

This is an SEC Form 4 insider transaction disclosure for Bluejay Diagnostics, Inc. (BJDX).

Company-level read

Ticker impact

$BJDXBullishMedium confidence
Context

HRT Financial LP, a 10% owner, filed a Form 4 showing an open-market purchase of 64,047 BJDX shares at $1.51 on 2026-07-09.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than a re-rating catalyst.

Evidence & confidence

Form 4 provides a fresh, primary datapoint (new purchase), yet it does not include guidance, trial results, financing, or other company-specific fundamentals that typically drive repricing.

Market effects

No clear sector read-through; this is a single-company ownership transaction.

None indicated.

None indicated.

Counterpoint

The purchase may be routine portfolio rebalancing or driven by liquidity/plan mechanics, so it may not reflect a bullish view on near-term fundamentals.

Key entities

  • Bluejay Diagnostics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • HRT Financial LP

    Reported an open-market purchase of BJDX shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BJDXMed

Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update Completes SYMON-II clinical study enrollment and advances clinical validation activities Achieves critical manufacturing milestone ahead of contractual deadline, strengtheni

$BJDXMedAI 8/10

Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 For Immediate Release Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock. SYMON-II Clinical Validation Dataset Represents a Key Milestone as Bluejay Advances the Symphony™ IL-6 Test Towar

$BJDXMedAI 8/10

Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock

Bluejay Diagnostics (NASDAQ:BJDX) announced baseline clinical data from its SYMON-II study, evaluating IL-6 as a biomarker for 28-day mortality risk in sepsis patients. The study included 777 patients, with an 18% mortality rate. The company aims to use this data to support a regulatory submission for its Symphony IL-6 Test, which is not yet FDA-approved.